We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Precise Diagnosis of Mitochondrial Diseases Using Whole Genome Sequencing

By LabMedica International staff writers
Posted on 15 Nov 2021
A team of British researchers has demonstrated that a whole genome sequencing approach could identify patients with difficult to diagnose mitochondrial diseases and distinguish them from non-mitochondrial disorders.

Mitochondrial disorders are a common cause of inherited metabolic disease, affecting approximately 1 in 5000 people. More...
They are caused by mutations in genes that primarily affect oxidative phosphorylation and ATP synthesis. Mitochondrial diseases take on unique characteristics both because of the way the diseases are often inherited and because mitochondria are so critical to cell function. Mitochondrial diseases are usually detected by analyzing muscle samples, where the presence of these organelles is higher. However, current genetic testing regimes fail to diagnose around 40% of patients, with major implications for patients.

In an effort to improve the diagnostics situation, investigators at the University of Cambridge (United Kingdom) and their colleagues at other institutions conducted a study to determine whether whole genome sequencing (WGS) could be used to define the molecular basis of suspected mitochondrial disorders.

For this study, the investigators performed short read whole genome sequencing on blood samples obtained from 345 patients with suspected mitochondrial disorders who were participants in the 100,000 Genomes Project in England between 2015 and 2018. The 100,000 Genomes Project was set up to embed genomic testing in the British National Health System, discover new disease genes, and make genetic diagnosis available for more patients.

Results obtained during the study revealed a definite or probable genetic diagnosis in 98/319 (31%) families, with an additional six (2%) possible diagnoses. Fourteen of the diagnoses (4% of the 319 families) explained only part of the clinical features. A total of 95 different genes were implicated. Of 104 families given a diagnosis, 39 (38%) had a mitochondrial diagnosis and 65 (63%) had a non-mitochondrial diagnosis.

The results showed that WGS was a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31% after exclusion of common causes. Most diagnoses were non-mitochondrial disorders and included developmental disorders with intellectual disability, epileptic encephalopathies, other metabolic disorders, cardiomyopathies, and leukodystrophies. If a targeted approach had been taken, these diagnoses would have been missed.

Senior author Dr. Patrick Chinnery, professor of neurology at the University of Cambridge, said, “We recommend that whole genome sequencing should be offered early and before invasive tests such as a muscle biopsy. All that patients would need to do is have a blood test, meaning that this could be offered across the whole country in an equitable way. People would not need to travel long distances to multiple appointments, and they would get their diagnosis much faster.”

Considering that the majority of diagnoses were of non-mitochondrial disorders, Dr. Chinnery said, “These patients were referred because of a suspected mitochondrial disease and the conventional diagnostic tests are specifically for mitochondrial diseases. Unless you consider these other possibilities, you will not diagnose them. Whole genome sequencing is not restricted by that bias.”

The study was published in the November 4, 2021, online edition of the journal BMJ.

Related Links:
University of Cambridge


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.